Four centrosome-related genes to predict the prognosis and drug sensitivity of patients with colon cancer

Figure 5 Analysis of tumor microenvironments and response to immunotherapy among patients with high- and low-risk centrosome-related signature. A: The fraction of 22 CIBERSORT immune cell types in high- and low-risk subgroups; B: The correlation between each signature gene and 16 immune cell types using CIBERSORT; C-E: The correlation between the risk score of centrosome-related signature (CRS) and immune cell types using CIBERSORT; F: Comparison of the tumor microenvironment scores between high- and low-risk CRS using ESTIMATE. Stromal score and estimate score were significantly higher in the high-risk CRS group than in the low-risk CRS group (P < 0.01 and P < 0.05, respectively). No significant difference was found between these two groups for the immune score; G and H: Tumor immune dysfunction and exclusion algorithm showed patients with a high-risk signature were insensitive to immunotherapy. ^aP < 0.05. ^bP < 0.01. ^cP < 0.001 vs high-risk and low-risk groups.